Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021
February 17 2021 - 8:05AM
Amarin Corporation plc (NASDAQ:AMRN) today announced that it will
host a conference call with members of Amarin senior management to
discuss the company's fourth quarter and full year 2020 financial
results and provide an operational update on Thursday, February 25,
2021, at 7:30 a.m. ET. The conference call will follow the
anticipated release of the company's financial results earlier that
day.
Conference Call and Webcast Information:
Amarin will host a conference call February 25,
2021, at 7:30 a.m. ET to discuss this information. The conference
call can be heard live on the investor relations section of the
company's website at www.amarincorp.com, or via telephone by
dialing 877-545-0320 within the United States, 973-528-0016 from
outside the United States, and referencing conference ID 635842. A
replay of the call will be made available for a period of two weeks
following the conference call. To hear a replay of the call, dial
877-481-4010, PIN: 40090. A replay of the call will also be
available through the company's website shortly after the call.
To Ask Questions:
During the teleconference, following prepared
remarks, management will respond to questions from investors and
analysts, subject to time limitations. Participants in the live
teleconference will be provided an opportunity to ask questions.
Investors may also e-mail their questions to
investor.relations@amarincorp.com. Email questions will be accepted
until Wednesday, February 24, 2021 at 4:00 p.m. ET.
About Amarin
Amarin is a rapidly growing, innovative
pharmaceutical company leading a new paradigm in cardiovascular
disease management. From our scientific research foundation to our
focus on clinical trials, and now our commercial expansion, we are
evolving and growing. In 2009, Amarin had fewer than twenty
employees. Today, with offices in Bridgewater, New Jersey in the
United States, Dublin in Ireland, and Zug in Switzerland, Amarin
has approximately 1,000 employees and commercial partners and
suppliers around the world. We are committed to rethinking
cardiovascular risk through the advancement of scientific
understanding of the impact on society of significant residual risk
that exists beyond traditional therapies, such as statins for
cholesterol management.Availability of Other Information
About Amarin
Investors and others should note that Amarin
communicates with its investors and the public using the company
website (http://www.amarincorp.com), the investor relations website
(investor.amarincorp.com), including but not limited to investor
presentations and investor FAQs, Securities and Exchange Commission
filings, press releases, public conference calls and webcasts. The
information that Amarin posts on these channels and websites could
be deemed to be material information. As a result, Amarin
encourages investors, the media, and others interested in Amarin to
review the information that is posted on these channels, including
the investor relations website, on a regular basis. This list of
channels may be updated from time to time on Amarin’s investor
relations website and may include social media channels. The
contents of Amarin’s website or these channels, or any other
website that may be accessed from its website or these channels,
shall not be deemed incorporated by reference in any filing under
the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:Investor RelationsAmarin
Corporation plcIn U.S.: +1 (908) 719-1315 IR@amarincorp.com
(investor inquiries)
Solebury Troutamarinir@troutgroup.com
Media Inquiries:CommunicationsAmarin Corporation
plcIn U.S.: +1 (908) 892-2028 PR@amarincorp.com (media
inquiries)
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarin (NASDAQ:AMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024